Department of Urology, Emory University School of Medicine, Atlanta, Georgia.
Cancer. 2018 Jul 15;124(14):2897-2905. doi: 10.1002/cncr.31355. Epub 2018 Mar 26.
The rising cost of health care in the United States has been the focus of intense debate within the medical, legal, and legislative arenas, with the cost of cancer care representing an important component. Cost effectiveness is not always easy to define, and there is no standard metric in assessing this measure related to cancer therapies. Significant controversy surrounds exactly what is the appropriate cost per added year of life. This review examines cost, effectiveness, and comparative cost effectiveness of novel systemic therapies for patients with urologic malignancies. Cancer 2018;124:2897-905. © 2018 American Cancer Society.
美国不断上涨的医疗成本一直是医疗、法律和立法领域激烈争论的焦点，癌症护理的成本则是其中一个重要组成部分。成本效益并不总是那么容易定义，而且在评估癌症治疗相关措施时也没有标准的衡量标准。对于增加的每一年生命的适当成本具体是多少，这一问题存在着巨大的争议。本综述考察了新型系统疗法治疗泌尿系统恶性肿瘤患者的成本、疗效和相对成本效益。癌症 2018;124:2897-905。©2018 美国癌症协会。
